Diasorin announces new distribution agreement with Fisher Scientific

Diasorin announced that, following the recent 510(k) clearance and CLIA-waiver from the U.S. Food and Drug Administration (FDA) for its first assay—the FLU A/B, RSV & COVID-19 Panel for use on the LIAISON NES platform— the Company has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, for the LIAISON NES molecular point-of-care (POC) platform in the U.S. hospital market.

The LIAISON NES is a next-generation molecular POC system designed to expand access to high-quality diagnostic testing in decentralized settings. Its fully automated workflow requires only a few seconds of hands-on time and delivers results in approximately 15 minutes, enabling timely clinical decisions while reducing dependence on specialized laboratory personnel.

Read Diasorin's announcement for more information